Table 2 Demographics of GBM patients for marker development > 
From: Proteomic analysis predicts anti-angiogenic resistance in recurred glioblastoma
Characteristics | Responder (n = 7) | Non-responder (n = 7) | P-value |
|---|---|---|---|
Age | 56.71 ± 6.767 | 57.43 ± 2.224 | 0.9218 |
Gender | Male (n = 6) | Male (n = 2) |  |
|  | Female (n = 1) | Female (n = 5) |  |
Molecular type | |||
 IDH wild type | 3 | 3 |  |
 MGMT promoter status (methylated/unmethylated/NA) | 0/4/3 | 0/1/6 |  |
Surgical resection type | |||
 Partial resection | 1 | 3 |  |
 Gross total resection | 6 | 4 |  |
 TMZ duration | 354.7 ± 98.07 | 306.9 ± 89.22 | 0.7244 |
 Pre-Avastin KPS | 60 ± 4.364 | 50 ± 5.774 | 0.1922 |
 Overall survival (days) | 828.6 ± 91.21 | 771.1 ± 172.6 | 0.7736 |
 Progression free survival (days) | 277 ± 71.79 | 458 ± 83.35 | 0.1258 |
 Avastin dose (mg/kg) | 685.7 ± 40.41 | 595.7 ± 22.24 | 0.0748 |
 Initial tumor size (mm3) | 20710 ± 5902 | 28653 ± 6692 | 0.3909 |
 Recurred tumor size (mm3) | 37549 ± 12,339 | 23238 ± 6398 | 0.3235 |
 TMZ + AVASTIN | n = 7 | n = 7 |  |
 Mono therapy | 0 | 0 |  |